Rigel Pharmaceuticals, Inc. (Rigel), incorporated in June 1996, is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Closing share price